Capsule Summaries


Share

Program Content

Activities

  • E/C/F/TAF and M184V/I
    Study 1824: Virologic Suppression Maintained in Patients With M184V/I Mutation After Switch to EVG/COBI/FTC/TAF
    Capsule Summary
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 25, 2018

  • DRIVE-FORWARD: Week 96 Follow-up
    DRIVE-FORWARD: Durable Virologic Efficacy With Doravirine Plus NRTIs vs Darunavir/Ritonavir Plus NRTIs Through Week 96 in ART-Naive Patients
    Capsule Summary
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 25, 2018

  • GEMINI-1 and -2
    GEMINI-1 and -2: Dual-Therapy With DTG Plus 3TC Noninferior to DTG Plus FTC/TDF in Treatment-Naive Patients at Week 48
    Capsule Summary
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 26, 2018

  • Tsepamo: DTG and Neural Tube Defects
    Tsepamo: Preliminary Data Suggest Increased Risk of Neural Tube Defects With Dolutegravir Exposure at Conception
    Capsule Summary
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 27, 2018

  • Prevenir Interim Analysis
    Prevenir: Interim Analysis Shows High Efficacy of Daily or On-Demand PrEP Among MSM
    Capsule Summary
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 27, 2018

  • PARTNER2
    PARTNER2: Risk of HIV Transmission From HIV-Positive Partner on Suppressive ART Is Effectively Zero for MSM
    Capsule Summary
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 27, 2018

  • BRIGHTE Subgroup Analysis
    BRIGHTE: Fostemsavir Plus OBT Associated With Similar Virologic Efficacy in Most Subgroups of Heavily Treatment–Experienced Patients at Week 24
    Capsule Summary
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 30, 2018

  • SWORD-1, -2: Week 100 Follow-up
    SWORD-1 and -2: Durable Virologic Efficacy Through Week 100 With Switch From Baseline ART to DTG Plus RPV in Virologically Suppressed Patients
    Capsule Summary
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 31, 2018

Provided by

ProCE Banner

Supporters

Janssen

ViiV Healthcare

Partners

AIDS 2018

ProCE Banner

IAS 2018

ProCE Banner